WASHINGTON, DC--(Marketwired - Jul 16, 2013) - The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that the third annual Regen Med Partnering Forum will take place October 14 and 15, 2013 as part of the Stem Cell Meeting on the Mesa. This forum is the only partnering meeting organized specifically for the regenerative medicine field, and has become the premier gathering place for more than 300 senior level executives seeking opportunities to collaborate and learn more about recent advances in the space. Life Technologies Corporation (
The Regen Med Partnering Forum will take place at the Estancia La Jolla Hotel & Spa, La Jolla, California. The Stem Cell Meeting on the Mesa's eighth Annual Scientific Symposium will immediately follow the Regen Med Partnering Forum on October 16, 2013 at the Salk Institute for Biological Studies. The Scientific Symposium, organized by the Sanford Consortium for Regenerative Medicine, is attended by leading scientists and researchers in the field, as well as participants from the business and patient advocacy communities. Combined, these meetings will attract over 800 attendees from around the globe, highlighting the promise and progress of this rapidly evolving, interdisciplinary field.
"Stem Cell Meeting on the Mesa is the premier annual meeting for anyone involved in regenerative medicine, cell therapy and stem cell research," said Geoff MacKay, President & Chief Executive Officer of Organogenesis Inc. and Chairman of ARM. "The quality of speakers -- both industry and academic -- combined with high-level partnering opportunities, makes attending this meeting every year a top priority."
In addition to presentations by 40 cutting-edge companies seeking partners and investors, the Regen Med Partnering Forum will include interactive panels addressing critical commercial, scientific, regulatory and reimbursement issues. One-on-one meetings will also be scheduled with a state-of-the-art partnering system to connect participants. The Regen Med Partnering Forum was developed by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine (CIRM) in 2011 and has grown 35% over the past three years.
"Life Technologies has sponsored this meeting since its inception in 2006, and helped it grow into a leading, annual conference for the regenerative medicine community," said Alaine Maxwell, Associate Director, Americas Marketing, Stem Cells and Translational Research, Life Technologies. "Whether your goal is to gain exposure to researchers or put your name out in front of C-level executives, attending this meeting has incredible value."
To learn more or to register for the 2013 Stem Cell Meeting on the Mesa please visit www.stemcellmeetingonthemesa.com. Registration is complimentary for investors and credentialed members of the media.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.
About Life Technologies
Life Technologies Corporation (
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.